Global histone modification pattern associated with recurrence and disease-free survival in non-small cell lung cancer patients

Pathology International

Volumn 62, Issue 3, 2012, Pages 182-190

  Song, Joon Seon ^a   Kim, Yong Seok ^b   Kim, Dong Kwan ^a   Park, Sung il ^a   Jang, Se Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Hanyang University   (South Korea)

Author keywords

Acetylation; Histone; Methylation; Non small cell lung cancer; Recurrence

Indexed keywords

HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER TISSUE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; SCORING SYSTEM; TUMOR DIFFERENTIATION;

ACETYLATION; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HISTONES; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; METHYLATION; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862792039     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2011.02776.x     Document Type: Article

References (45)

1. Office KNS, ed. Annual report on the cause of death statistics, each year. 2005.
2. World Health Organization[homepage on the Internet]. Fact sheet N0297. Cancer 2006; (Accessed February 2006) Available from
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
4. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-17.
5. Kurdistani SK. Histone modifications as markers of cancer prognosis: A cellular view. Br J Cancer 2007; 97: 1-5.
6. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997; 389: 251-60.
7. Sims RJ 3rd, Nishioka K, Reinberg D. Histone lysine methylation: A signature for chromatin function. Trends Genet 2003; 19: 629-39.
8. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000; 403: 41-5.
9. Zhang Y, Reinberg D. Transcription regulation by histone methylation: Interplay between different covalent modifications of the core histone tails. Genes Dev 2001; 15: 2343-60.
10. Peterson CL, Laniel MA. Histones and histone modifications. Curr Biol 2004; 14: R546-51.
11. Suka N, Suka Y, Carmen AA, Wu J, Grunstein M. Highly specific antibodies determine histone acetylation site usage in yeast heterochromatin and euchromatin. Mol Cell 2001; 8: 473-9.
12. Rundlett SE, Carmen AA, Suka N, Turner BM, Grunstein M. Transcriptional repression by UME6 involves deacetylation of lysine 5 of histone H4 by RPD3. Nature 1998; 392: 831-5.
13. Vogelauer M, Wu J, Suka N, Grunstein M. Global histone acetylation and deacetylation in yeast. Nature 2000; 408: 495-8.
14. Seligson DB, Horvath S, Shi T etal. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005; 435: 1262-6.
15. Travos WD, Brambilla E, Konrad Müller-Hermelink H, Harris CC. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004; 10.
16. Kononen J, Bubendorf L, Kallioniemi A etal. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-7.
17. Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ. The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 2008; 15: 1968-76.
18. Marushige K. Activation of chromatin by acetylation of histone side chains. Proc Natl Acad Sci U S A 1976; 73: 3937-41.
19. Profumo A, Querzola F, Vidali G. Core histone acetylation during lymphocyte activation. FEBS Lett 1989; 250: 297-300.
20. Heard E, Rougeulle C, Arnaud D, Avner P, Allis CD, Spector DL. Methylation of histone H3 at Lys-9 is an early mark on the X chromosome during X inactivation. Cell 2001; 107: 727-38.
21. Mermoud JE, Popova B, Peters AH, Jenuwein T, Brockdorff N. Histone H3 lysine 9 methylation occurs rapidly at the onset of random X chromosome inactivation. Curr Biol 2002; 12: 247-51.
22. Nguyen CT, Weisenberger DJ, Velicescu M etal. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res 2002; 62: 6456-61.
23. Nakayama J, Rice JC, Strahl BD, Allis CD, Grewal SI. Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science 2001; 292: 110-13.
24. Schotta G, Lachner M, Sarma K etal. A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev 2004; 18: 1251-62.
25. Marks PA. Cancer. Principles and Practice of Oncology, 7th edn. Philadelphia, Pa: Lippincott Williams and Wilkins, 2005; 439-45.
26. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-28.
27. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005; 23: 3971-93.
28. Gibbons RJ. Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. Hum Mol Genet 2005; 14 Spec No 1: R85-92.
29. Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev 2004; 18: 2315-35.
30. Fraga MF, Ballestar E, Villar-Garea A etal. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37: 391-400.
31. Kim H, Kwon YM, Kim JS etal. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J Clin Oncol 2004; 22: 2363-70.
32. Barlesi F, Giaccone G, Gallegos-Ruiz MI etal. Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol 2007; 25: 4358-64.
33. Wiencke JK, Zheng S, Morrison Z, Yeh RF. Differentially expressed genes are marked by histone 3 lysine 9 trimethylation in human cancer cells. Oncogene 2007; 27: 2412-21.
34. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997; 389: 349-52.
35. Toh Y, Ohga T, Endo K etal. Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. Int J Cancer 2004; 110: 362-7.
36. Archer SY, Hodin RA. Histone acetylation and cancer. Curr Opin Genet Dev 1999; 9: 171-4.
37. Phillips AC, Vousden KH. Acetyltransferases and tumour suppression. Breast Cancer Res 2000; 2: 244-6.
38. Timmermann S, Lehrmann H, Polesskaya A, Harel-Bellan A. Histone acetylation and disease. Cell Mol Life Sci 2001; 58: 728-36.
39. Wang C, Fu M, Mani S, Wadler S, Senderowicz AM, Pestell RG. Histone acetylation and the cell-cycle in cancer. Front Biosci 2001; 6: D610-29.
40. Archer SY, Meng S, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci U S A 1998; 95: 6791-6.
41. Butler LM, Webb Y, Agus DB etal. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res 2001; 7: 962-70.
42. Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res 2004; 91: 137-68.
43. Sugimura H, Mori H, Nagura K etal. Fluorescence in situ hybridization analysis with a tissue microarray: 'FISH and chips' analysis of pathology archives. Pathol Int 2010; 60: 543-50.
44. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000; 80: 1943-9.
45. Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 2004; 17: 790-97.